Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer

Table 6

CRC recurrence detection by plasma mSEPT9 during follow-up.

Number ID	Gender	Age	TNM staging	Treat.	Period (months)	mSEPT 9	CEA	Recurrent status
1	Female	61	T4aN1bM0	S + C	22	−	2.53	Lung metastases
2	Female	42	T2N0M0	S	16	−	1.58	NER
3	Male	59	T3N0M0	S	9	−	2.04	NER
4	Male	53	T2N0M0	S	2	−	2.40	NER
5	Female	64	T2N0M0	S	77	+	75.85	Abdominal wall metastases
6	Female	63	T3N1aM0	S + C	36	−	1.68	NER
7	Female	52	T3N1aM0	S + C	8	−	2.32	NER
8	Male	58	T4aN0M0	S + C	24	−	2.62	NER
9	Male	56	T3N0M0	S	48	−	2.25	NER
10	Male	58	T2N0M0	S + C	8	−	1.59	NER
11	Female	62	T3N0M0	S	24	−	4.29	NER
12	Female	61	TisN0M0	S	34	−	1.70	NER
13	Male	42	T3N0M0	S + C	20	−	0.76	NER
14	Male	60	T3N0M0	S	102	+	1.41	Recurrent CRC
15	Male	43	T2N0M0	S	3	−	2.59	NER
16	Female	60	T4aN0M0	S + C	11	+	7.59	Liver metastases

Treat.: treatment; S: curatively intended surgery; C: chemotherapy; NER: no evidence of recurrence; +: positive; −: negative; boldface in CEA column represents positive; : period after treatment.